Inactive Instrument

Sterling Green Group PLC London S.E.

GB00B1N0T068

Pharmaceuticals

End-of-day quote London S.E. Other stock markets
- ^GBX	-

2023	Amryt Pharma plc(NasdaqGS:AMYT) dropped from S&P Global BMI Index	CI
2023	Amryt Pharma plc(NasdaqGS:AMYT) dropped from NASDAQ Composite Index	CI

Fastnet Oil & Gas PLC : Posting of Accounts and Restoration of dealings 14/11/11

January 03, 2013 at 03:52 am EST

MarketScreener.com By

Released :
14/11/2011

14 November
Sterling Green Group plc
("Sterling Green" or "the Company")

Posting of Accounts and Restoration of dealings

Further to the announcement made earlier today the Company advises that the report and accounts for the year ended 31 March 2011 will be posted to shareholders today. Accordingly, the Company has requested restoration of dealings in the Company's shares on AIM and it is expected that dealings will be restored at 7.30am today.

The report and accounts for the year ended 31 March 2011 are now available on the Company's website - www.sterlinggreen.co.uk.

Further enquiries:
Sterling Green Group plc Tel: 0161 975 5757

Michael Edelson

Merchant Securities Limited Tel: 020 7628 2200

Simon Clements/David Worlidge

distributed by

Latest news about Sterling Green Group PLC

Amryt Pharma plc(NasdaqGS:AMYT) dropped from S&P Global BMI Index	23-04-13	CI
Amryt Pharma plc(NasdaqGS:AMYT) dropped from NASDAQ Composite Index	23-04-12	CI
Chiesi Farmaceutici S.p.A. completed the acquisition of Amryt Pharma plc from Athyrium Capital Management, LP, Highbridge Capital Management, LLC, Joe Wiley, Rory Nealon, Ray Stafford and others.	23-04-11	CI
Amryt Pharma's Shareholders Approve Acquisition by Chiesi Farmaceutici	23-03-22	MT
Amryt Pharma plc’s Equity Buyback announced on March 9, 2022, has expired.	23-03-07	CI
HC Wainwright Downgrades Amryt Pharma to Neutral From Buy, Cuts Price Target to $14.50 From $18	23-01-18	MT
Maxim Group Downgrades Amryt Pharma to Hold From Buy	23-01-10	MT
Cantor Fitzgerald Downgrades Amryt Pharma to Neutral From Overweight, Adjusts Price Target to $14.75 From $25	23-01-10	MT
Canaccord Genuity Downgrades Amryt Pharma to Hold From Buy, Adjusts Price Target to $17 From $19	23-01-10	MT
Sector Update: Health Care Stocks Largely Struggle Monday	23-01-09	MT
Top Midday Gainers	23-01-09	MT
Sector Update: Health Care Stocks Struggling to Begin New Week	23-01-09	MT
Sector Update: Health Care	23-01-09	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	23-01-09	MT
Rate Hike Clues, China Border Reopening Fuel Gains for US Equity Futures	23-01-09	MT
Top Premarket Gainers	23-01-09	MT
Amryt Pharma to be Acquired by Chiesi Farmaceutici	23-01-09	MT
Italy's Chiesi Farmaceutici to Buy Rare Disease-focused Amryt Pharma for $1.5 Billion	23-01-09	MT
Chiesi Farmaceutici S.p.A. entered into a definitive agreement to acquire Amryt Pharma plc from Athyrium Capital Management, LP, Highbridge Capital Management, LLC, Joe Wiley, Rory Nealon, Ray Stafford and others for $1.1 billion.	23-01-07	CI
Amryt Pharma Says Phase 3 Trial of Cholesterol Disorder Treatment Met Primary Endpoint; Shares Gain Pre-Bell	23-01-05	MT
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH	23-01-05	CI
Amryt Says European Medicines Agency Committee Adopts Positive Opinion on Orphan Designation for Mycapssa	22-12-19	MT
Amryt Pharma Receives Approval for Mycapssa in Europe	22-12-05	MT
Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly	22-12-05	CI
Amryt Pharma Says It Received New US Patent for Mycapssa	22-11-30	MT

Chart Sterling Green Group PLC

Duration

Period

More charts

Company Profile

Amryt Pharma plc is a commercial-stage biopharmaceutical company. It is focused on acquiring, developing, and commercializing novel treatments for rare diseases. Its commercial business comprises three orphan disease products, such as metreleptin (Myalept/ Myalepta); lomitapide (Juxtapid/ Lojuxta), and oral octreotide (Mycapssa). Myalept is approved in the United States as an adjunct to diet as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalised lipodystrophy (GL). Juxtapid is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, homozygous familial hypercholesterolaemia (HoFH). Mycapssa is a combination of octreotide acetate and excipients, collectively called Transient Permeability Enhancer (TPE). Its development candidate, Oleogel-S10 (Filsuvez) is a treatment for the cutaneous manifestations of junctional and dystrophic (JEB and DEB) epidermolysis bullosa.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	+6.96%	101B
SAMSUNG BIOLOGICS CO.,LTD.	+8.29%	42.63B
UCB	+82.32%	29.77B
BIOMARIN PHARMACEUTICAL INC.	-11.82%	16.14B
INCYTE CORPORATION	+1.39%	14.31B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.13%	11.55B
ALTEOGEN INC.	+176.65%	10.53B
SWEDISH ORPHAN BIOVITRUM AB	+6.74%	9.2B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-55.52%	8.98B

Biopharmaceuticals

Sterling Green Group PLC London S.E.

Equities

GB00B1N0T068

Pharmaceuticals

Fastnet Oil & Gas PLC : Posting of Accounts and Restoration of dealings 14/11/11

Latest news about Sterling Green Group PLC

Chart Sterling Green Group PLC

Company Profile

Sector Biopharmaceuticals